BioWorld

Nov. 3, 2006

XOMA, Takeda In Antibody Deal With $100M Potential

XOMA Ltd. could receive more than $100 million in a collaboration with Takeda Pharmaceutical Co. Ltd. to discover and develop monoclonal antibody therapeutics. (BioWorld Today) Read More

Exelixis' Stock Falls After XL999 Phase II Suspension

TopoTarget, LEO Deal Gives CuraGen Payoff For License

Gamida Cell Earns SPA To Begin Phase III For StemEx

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...